Home
Drugs
Palbociclib
Clinical Trials

Clinical Trials Related to Palbociclib

Related studies linked through entity extraction aliases.

Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Status: UNKNOWN
Phase: PHASE2

Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer

Status: UNKNOWN
Phase: N/A

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Status: TERMINATED
Phase: PHASE2

High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)

Status: UNKNOWN
Phase: PHASE2

A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

Status: COMPLETED
Phase: PHASE2

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2/PHASE3

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy

Status: COMPLETED
Phase: EARLY_PHASE1

Palbociclib + Ganitumab In Ewing Sarcoma

Status: TERMINATED
Phase: PHASE2

Analysis of Palbociclib Treatment in Patients With Advanced Breast Cancer Within a Compassionate Use Programe

Status: COMPLETED
Phase: N/A

A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer

Status: COMPLETED
Phase: PHASE2

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Status: TERMINATED
Phase: PHASE1

Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer

Status: COMPLETED
Phase: PHASE2

Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer

Status: COMPLETED
Phase: PHASE3

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

UK Ibrance Patient Program (IPP) Study

Status: COMPLETED
Phase: N/A

Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Status: TERMINATED
Phase: PHASE1

Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients

Status: ACTIVE_NOT_RECRUITING
Phase: NA

WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Status: COMPLETED
Phase: PHASE1